Home Higher serum caspase-cleaved cytokeratin-18 levels during the first week of sepsis diagnosis in non-survivor patients
Article
Licensed
Unlicensed Requires Authentication

Higher serum caspase-cleaved cytokeratin-18 levels during the first week of sepsis diagnosis in non-survivor patients

  • Leonardo Lorente EMAIL logo , María M. Martín , Antonia Pérez-Cejas , Raquel Ortiz López , José Ferreres , Jordi Solé-Violán , Lorenzo Labarta , César Díaz , Salomé Palmero , Manuel Buitrago , Alejandro Jiménez and Juan M. Borreguero-León
Published/Copyright: March 7, 2017

Abstract

Background:

Caspase-cleaved cytokeratin (CCCK)-18 is a protein released into the blood during apoptosis. Higher circulating CCCK-18 concentrations have been found in non-survivor than in survivor septic patients at moment of sepsis diagnosis. The following questions arise now: (1) How are serum CCCK-18 levels during the first week of sepsis? (2) Is there an association between sepsis severity and mortality and serum CCCK-18 levels during the first week? The aims of this study were to answer these questions.

Methods:

Multicenter study with 321 severe septic patients from eight Spanish intensive care units. We determined serum concentration of CCCK-18, tumor necrosis factor (TNF)-α, and interleukin (IL)-10 during the first week. Our end-point study was 30-day mortality.

Results:

Non-survivor (n=108) compared to survivor patients (n=213) showed higher serum CCCK-18 levels at days 1, 4 and 8 (p<0.001). ROC curve analyses showed that serum CCCK-18 levels at days 1 (AUC=0.77; 95% CI=0.72–0.82), 4 (AUC=0.81; 95% CI=0.76–0.85) and 8 (AUC=0.83; 95% CI=0.78–0.88) could predict mortality at 30 days (p<0.001). Logistic regression analyses showed that serum CCCK-18 levels at days 1 (OR=4.367; 95% CI=2.491–7.659), 4 (OR=10.137; 95% CI=4.741–21.678) and 8 (OR=8.781; 95% CI=3.626–21.268) were associated with 30-day mortality (p<0.001). We found a positive correlation between CCCK-18, SOFA, and lactic acid at days 1, 4 and 8.

Conclusions:

Non-survivor septic patients showed persistently during the first week higher serum CCCK-18 levels than survivor patients, and there is an association between sepsis severity and mortality and serum CCCK-18 levels during the first week.

  1. Author contributions: L.Lo. conceived, designed and coordinated the study, participated in acquisition and interpretation of data, and drafted the manuscript. M.M.M., R.O.L., J.F., J.S.V., L.La., C.D., S.P., M.B. participated in acquisition of data. APC and JMBL participated in blood determination levels. A.J. participated in the interpretation of data. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This study was supported by grants from Instituto de Salud Carlos III (PI14/00220 and INT16/00165) (Madrid, Spain) and co-financed by Fondo Europeo de Desarrollo Regional (FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310.10.1097/00003246-200107000-00002Search in Google Scholar

2. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344–53.10.1097/01.CCM.0000194725.48928.3ASearch in Google Scholar

3. Huttunen R, Aittoniemi J. New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J Infect 2011;63:407–19.10.1016/j.jinf.2011.08.004Search in Google Scholar

4. Harjai M, Bogra J, Kohli M, Pant AB. Is suppression of apoptosis a new therapeutic target in sepsis? Anaesth Intensive Care 2013;41:175–83.10.1177/0310057X1304100207Search in Google Scholar

5. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 2005;12(Suppl 1):942–61.10.1038/sj.cdd.4401556Search in Google Scholar

6. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007;8:493–500.10.2174/138945007780362764Search in Google Scholar

7. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403–39.10.1046/j.1365-2559.2002.01387.xSearch in Google Scholar

8. Caulín C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 1997;138:1379–94.10.1083/jcb.138.6.1379Search in Google Scholar

9. Hägg M, Bivén K, Ueno T, Rydlander L, Björklund P, Wiman KG, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002;20:253–9.10.1023/A:1016249728664Search in Google Scholar

10. Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. Blood 1999;187:567–72.10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-JSearch in Google Scholar

11. Luft T, Conzelmann M, Benner A, Rieger M, Hess M, Strohhaecker U, et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 2007;110:4535–42.10.1182/blood-2006-10-049817Search in Google Scholar

12. Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 2003;39:769–74.10.1016/S0959-8049(02)00865-1Search in Google Scholar

13. Greystoke A, O’Connor JP, Linton K, Taylor MB, Cummings J, Ward T, et al. Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer 2011;104:719–25.10.1038/sj.bjc.6606082Search in Google Scholar PubMed PubMed Central

14. Bantel H, Lügering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004;40:1078–87.10.1002/hep.20411Search in Google Scholar PubMed

15. Sgier C, Müllhaupt B, Gerlach T, Moradpour D, Negro F, Malé PJ, et al. Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. J Viral Hepat 2010;17:845–50.10.1111/j.1365-2893.2009.01251.xSearch in Google Scholar PubMed

16. Sumer S, Aktug Demir N, Kölgelier S, Cagkan Inkaya A, Arpaci A, Saltuk Demir L, et al. The clinical significance of serum apoptotic cytokeratin 18 neoepitope M30 (CK-18 M30) and matrix metalloproteinase 2 (MMP-2) levels in chronic hepatitis B patients with cirrhosis. Hepat Mon 2013;13:e10106.10.5812/hepatmon.10106Search in Google Scholar PubMed PubMed Central

17. Parfieniuk-Kowerda A, Lapinski TW, Rogalska-Plonska M, Swiderska M, Panasiuk A, Jaroszewicz J, et al. Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C. Liver Int 2014;34:544–50.10.1111/liv.12297Search in Google Scholar PubMed

18. Gu SJ, Lu M, Xuan HF, Chen XZ, Dong WF, Yan XF, et al. Predictive value of serum caspase-cleaved cytokeratin-18 concentrations after acute intracerebral hemorrhage. Clin Chim Acta 2016;452:124–8.10.1016/j.cca.2015.11.011Search in Google Scholar PubMed

19. Lorente L, Martín MM, González-Rivero AF, Argueso M, Ramos L, Solé-Violán J, et al. Serum levels of caspase-cleaved cytokeratin-18 in patients with severe traumatic brain injury are associated with mortality: a pilot study. PLoS One 2015;10:e0121739.10.1371/journal.pone.0121739Search in Google Scholar PubMed PubMed Central

20. Roth GA, Krenn C, Brunner M, Moser B, Ploder M, Spittler A, et al. Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients. Shock 2004;22:218–20.10.1097/01.shk.0000136098.49672.0eSearch in Google Scholar PubMed

21. Moore DJ, Greystoke A, Butt F, Wurthner J, Growcott J, Hughes A, et al. A pilot study assessing the prognostic value of CK18 and nDNA biomarkers in severe sepsis patients. Clin Drug Investig 2012;32:179–87.10.2165/11598610-000000000-00000Search in Google Scholar PubMed

22. Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstern C, Weitz J, et al. Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction. Crit Care 2009;13:R93.10.1186/cc7923Search in Google Scholar PubMed PubMed Central

23. Lorente L, Martín MM, González-Rivero AF, Ferreres J, Solé-Violán J, Labarta L, et al. Serum levels of caspase-cleaved cytokeratin-18 and mortality are associated in severe septic patients: pilot study. PLoS One 2014;9:e109618.10.1371/journal.pone.0109618Search in Google Scholar PubMed PubMed Central

24. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/ATS/SISInternational Sepsis Definitions Conference. Intensive Care Med 2003;29:530–8.10.1007/s00134-003-1662-xSearch in Google Scholar PubMed

25. Lorente L, Martín MM, Abreu-González P, Domínguez-Rodriguez A, Labarta L, Díaz C, et al. Sustained high serum malondialdehyde levels are associated with severity and mortality in septic patients. Crit Care 2013;17:R290.10.1186/cc13155Search in Google Scholar PubMed PubMed Central

26. Lorente L, Martín MM, Solé-Violán J, Blanquer J, Labarta L, Díaz C, et al. Association of sepsis-related mortality with early increase of timp-1/mmp-9 ratio. PLoS One 2014;9:e94318.10.1371/journal.pone.0094318Search in Google Scholar PubMed PubMed Central

27. Lorente L, Martín MM, López-Gallardo E, Blanquer J, Solé-Violán J, Labarta L, et al. Decrease of oxidative phosphorylation system function in severe septic patients. J Crit Care 2015;30:935–9.10.1016/j.jcrc.2015.05.031Search in Google Scholar PubMed

28. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. for the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine. The Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707–10.10.1007/BF01709751Search in Google Scholar PubMed

29. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–29.10.1097/00003246-198510000-00009Search in Google Scholar

30. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000;1:496–501.10.1038/82741Search in Google Scholar PubMed

31. Chung CS, Song GY, Lomas J, Simms HH, Chaudry IH, Ayala A. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J Leukoc Biol 2003;74:344–51.10.1189/jlb.0102006Search in Google Scholar PubMed

32. Wesche-Soldato DE, Chung CS, Lomas-Neira J, Doughty LA, Gregory SH, Ayala A. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 2005;106:2295–301.10.1182/blood-2004-10-4086Search in Google Scholar PubMed PubMed Central

33. Li P, Bledsoe G, Yang ZR, Fan H, Chao L, Chao J. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology 2014;142:216–26.10.1111/imm.12242Search in Google Scholar PubMed PubMed Central

34. Matsuda N, Teramae H, Futatsugi M, Takano K, Yamamoto S, Tomita K, et al. Up-regulation of histamine H4 receptors contributes to splenic apoptosis in septic mice: counteraction of the antiapoptotic action of nuclear factor-kappaB. J Pharmacol Exp Ther 2010;332:730–7.10.1124/jpet.109.163543Search in Google Scholar PubMed

35. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). J Am Med Assoc 2016;315:801–10.10.1001/jama.2016.0287Search in Google Scholar PubMed PubMed Central

Received: 2016-11-10
Accepted: 2017-1-26
Published Online: 2017-3-7
Published in Print: 2017-8-28

©2017 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Reporting LDL-cholesterol levels in the era of intensive lipid management: a clarion call
  4. The challenges of genetic risk scores for the prediction of coronary heart disease
  5. Reviews
  6. Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling
  7. A review of the challenge in measuring and standardizing BCR-ABL1
  8. Mini Review
  9. Challenges in the analysis of epigenetic biomarkers in clinical samples
  10. Opinion Paper
  11. Defining a roadmap for harmonizing quality indicators in Laboratory Medicine: a consensus statement on behalf of the IFCC Working Group “Laboratory Error and Patient Safety” and EFLM Task and Finish Group “Performance specifications for the extra-analytical phases”
  12. Genetics and Molecular Diagnostics
  13. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid
  14. General Clinical Chemistry and Laboratory Medicine
  15. A survey of patients’ views from eight European countries of interpretive support from Specialists in Laboratory Medicine
  16. Verification of examination procedures in clinical laboratory for imprecision, trueness and diagnostic accuracy according to ISO 15189:2012: a pragmatic approach
  17. Expressing analytical performance from multi-sample evaluation in laboratory EQA
  18. A candidate reference method for serum potassium measurement by inductively coupled plasma mass spectrometry
  19. Practical motives are prominent in test-ordering in the Emergency Department
  20. Technical and clinical validation of the Greiner FC-Mix glycaemia tube
  21. Comparison of pneumatic tube system with manual transport for routine chemistry, hematology, coagulation and blood gas tests
  22. Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay
  23. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry
  24. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease
  25. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases
  26. Hematology and Coagulation
  27. Critical appraisal of discriminant formulas for distinguishing thalassemia from iron deficiency in patients with microcytic anemia
  28. Reference Values and Biological Variations
  29. Reference ranges of thromboelastometry in healthy full-term and pre-term neonates
  30. Cancer Diagnostics
  31. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression
  32. Cardiovascular Diseases
  33. Assessment of the clinical utility of adding common single nucleotide polymorphism genetic scores to classical risk factor algorithms in coronary heart disease risk prediction in UK men
  34. Time and age dependent decrease of NT-proBNP after septal myectomy in hypertrophic obstructive cardiomyopathy
  35. Infectious Diseases
  36. Higher serum caspase-cleaved cytokeratin-18 levels during the first week of sepsis diagnosis in non-survivor patients
  37. Letters to the Editor
  38. Data mining for age-related TSH reference intervals in adulthood
  39. Intra-laboratory variation and its effect on gestational diabetes diagnosis
  40. Evaluation of long-term imprecision of automated complete blood cell count on the Sysmex XN-9000 system
  41. Sensitivity of the Sysmex XN9000 WPC-channel for detection of monoclonal B-cell populations
  42. Evaluation of biotin interference on immunoassays: new data for troponin I, digoxin, NT-Pro-BNP, and progesterone
  43. Stability of procalcitonin in cerebrospinal fluid
  44. Between-laboratory analysis of IgG antibodies against Aspergillus fumigatus in paired quality control samples
  45. Mass spectrometry vs. immunoassay in clinical and forensic toxicology: qui modus in rebus est?
  46. Great need for changes in higher education in Greece
  47. A note from the Editor in Chief regarding the Letter to the Editor “Great need for changes in higher education in Greece”
Downloaded on 1.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2016-1034/html
Scroll to top button